Profound Medical (NASDAQ:PROF; TSX:PRN) launched a newly designed TULSA Procedure website, for residents of the U.S. suffering from a prostate condition. “This new site aims to be credible and focused on providing clear...
Closely held Ennaid Therapeutics is advancing development of ENU200 as a therapeutic to treat the up to 80% of asymptomatic, mild-to-moderate cases of COVID-19 viral infections. ENU200 is a repurposed, patent-pending...
The FDA accepted for priority review Mesoblast’s (NASDAQ:MESO; ASX:MSB) biologics license application filing for RYONCIL, its allogeneic cell therapy for the treatment of children with steroid-refractory acute graft...
MEI Pharma’s (NASDAQ:MEIP) ME-401 received FDA fast track designation for the treatment of patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. The company is...
Closely held Zucara Therapeutics closed a $21-million Series A financing led by the Perceptive Xontogeny Venture (PXV) Fund. Proceeds will be used for Phase 1 and Phase 2 clinical trials of ZT-01, Zucara’s first-in...
Closely held Kleo Pharmaceuticals entered into a research collaboration with South Korea-based Green Cross LabCell, a pioneer in the next generation of allogeneic, or “off-the-shelf” natural killer cell...
Dr. Ali Kasraeian of the renowned Kasraeian Urology in Jacksonville, FL, in partnership with Vituro Health, treated their first patient with Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO medical device for...
Georgia’s renowned Busch Center is now offering Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO procedure to treat unhealthy prostate tissue. The technology, which was cleared by the FDA in August 2019, provides...
The board of Obalon Therapeutics (NASDAQ:OBLN) decided to explore potential financial and strategic alternatives intended to enhance stockholder value and has retained Canaccord Genuity as its financial advisor. The...
Prevail Therapeutics (NASDAQ:PRVL) received FDA fast track designation for PR006, a gene therapy candidate designed to slow the progression of frontotemporal dementia with a GRN mutation. Frontotemporal dementia is the...
Novavax (NASDAQ:NVAX) posted positive top-line results of its Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its Matrix-M adjuvant, in adults aged 65 and older...
Dicerna Pharma (NASDAQ:DRNA) received FDA orphan drug designation for DCR-A1AT for the treatment of alpha-1 antitrypsin deficiency, a genetic disorder that can cause lung and liver disease. The company submitted a...
NantKwest (NASDAQ:NK) dosed the first patient in its Phase 2 trial for second- and third-line Merkel cell carcinoma (MCC). MCC is a rare and aggressive skin cancer that is fatal for the majority of patients who have...
Soligenix (NASDAQ:SNGX) reported positive topline results for its Phase 3 trial assessing SGX301 for the treatment of cutaneous T-cell lymphoma (CTCL). The study enrolled 169 patients who were randomized to receive...
Abeona Therapeutics (NASDAQ:ABEO) treated the first patient in its Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The trial, being conducted at Stanford...
Alpine Immune Sciences (NASDAQ:ALPN) received two FDA orphan drug designations for ALPN-101 for the prevention and treatment of acute graft-versus-host disease (GvHD). ALPN-101 is a selective dual T-cell co-stimulation...
Closely-held Sigilon Therapeutics completed an $80.3-million Series B financing to advance its Shielded Living Therapeutics platform to the clinic. The funding will support the first-in-human clinical trial of Sigilon’s...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive findings from a translational research study assessing the effects of CRV431 on lung tissue obtained from a patient with idiopathic pulmonary fibrosis (IPF). In the...
Bee Vectoring Technologies International (TSXV, CVE:BEE; OTCQB:BEVVF) closed three new grower deals with berry producers in Oregon and Washington states to use the company’s proprietary bee delivery system, VECTORITE...
Albireo Pharma (NASDAQ:ALBO) completed patient enrollment in its Phase 2 trial of elobixibat for the treatment of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD). The trial enrolled 47...
According to the FDA, the passage of the 2018 Farm Bill has led to the misperception that all products made from or containing hemp, including those made with cannabidiol (CBD), were now legal to sell in interstate...
Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) has continued to collect additional input on its i/Blue Imaging System from physicians in the United States and Canada. Leading urologists...